Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a CoQ10 supplement counteract GLP-1 fatigue and muscle loss?

NCT ID NCT07789106

Symptom relief Sponsor: StudySetGo Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 27, 2026 · Last updated Sep 02, 2026 · Updated 3 times

Summary

This trial tests whether a daily ubiquinol supplement, a form of Coenzyme Q10, can reduce fatigue and help maintain muscle strength in adults aged 30-65 who are taking GLP-1 weight loss medications like Wegovy or Mounjaro. About 90 participants will take either ubiquinol or a placebo capsule every day for 9 months. Researchers will measure fatigue, muscle function, and quality of life through home nurse visits, monthly video calls, and smartphone app logging. The study is fully remote, so participants do not need to visit a clinic.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ubiquinol (a form of Coenzyme Q10) taken as a 100 mg oral capsule daily
What this could lead to
If it works, this could point toward a simple daily supplement that helps people on GLP-1 weight loss medications feel less tired and keep more muscle strength.
What could go wrong
This is a small, early-stage trial with 90 participants, so results may not apply broadly. The supplement might not outperform the placebo, and any benefit could be modest.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 90 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Sep 2028

An estimate. End dates often move.

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

30 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 30-65 years * Body mass index \>27kg/m2 and \<35 kg/m2 * Currently initiating, or has initiated within the preceding 4 weeks of screening, one of the following MHRA-licensed weight management pharmacotherapies: semaglutide 2.4mg (Wegovy®) or tirzepatide (Mounjaro®) prescribed for the indication of weight management. * Is physically mobile and able to complete 5x sit to stand movements * Owns a smartphone (iOS 15.6 or later, Android 9 or later) and is willing and able to install the SANNO Health app * Proficient in English language speaking and reading * Owns their own digital body weighing scale * Able and willing to provide full informed consent Exclusion Criteria: * Prior use of ubiquinol or Co-enzyme Q10 within 3 months of screening * Diagnosed condition which, in the opinion of the Chief investigator, may independently impact fatigue (e.g. type 1 or type 2 diabetes, cardiovascular disease, obstructive sleep apnoea, inflammatory or autoimmune conditions, cirrhotic or advanced liver disease, malignancy) * Prior or current use of statin medication * Has previously used GLP-1 agonists and/or undergone bariatric surgery * Other medications, which in the opinion of the Chief Investigator, may deplete CoQ10 * Failed screening bloods (any results that is outside of the lab reference range) * Intention to stop GLP-1 agonist use within 9 months of randomisation * Pregnancy, breastfeeding or intention to conceive during study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Fatigue severity scale are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Fatigue severity scale GLP-1 Muscle contraction Obesity & overweight Ubiquinol

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Office 1110 3 Fitzroy Place, 1/1, Sauchiehall Street

    Glasgow, G3 7RH, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.